Los Angeles Capital Management
SPRY icon

Los Angeles Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

Los Angeles Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.18K Sell
147
-65,599
-100% -$629K ﹤0.01% 2336
2025
Q4 		$567K Buy
+65,746
New +$639K ﹤0.01% 845
2024
Q3 		– Sell
-27,120
Closed -$231K – 1289
2024
Q2 		$231K Buy
+27,120
New +$241K ﹤0.01% 1096

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Los Angeles Capital Management's SPRY Position: Q1 2026 in Review

Los Angeles Capital Management reduced its ARS Pharmaceuticals (SPRY) stake by 100% in Q1 2026, selling an estimated $629K and leaving 147 shares worth $1.18K. The position accounts for ﹤0.01% of the portfolio, ranked #2336.

Los Angeles Capital Management first reported a position in SPRY in Q2 2024 and has held it in 3 quarters since. The position peaked at $567K in Q4 2025. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Los Angeles Capital Management held 147 shares of ARS Pharmaceuticals worth $1.18K as of Q1 2026.
  • Los Angeles Capital Management sold 65,599 ARS Pharmaceuticals shares in Q1 2026, an estimated $629K.
  • ARS Pharmaceuticals made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #2336 holding.
  • Los Angeles Capital Management first reported a position in ARS Pharmaceuticals in Q2 2024 and has held it in 3 quarters since.
  • Los Angeles Capital Management's ARS Pharmaceuticals position peaked at $567K in Q4 2025.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.